JP5245823B2 - 嚥下障害改善剤およびそれを含有する医薬又は食品組成物 - Google Patents
嚥下障害改善剤およびそれを含有する医薬又は食品組成物 Download PDFInfo
- Publication number
- JP5245823B2 JP5245823B2 JP2008513113A JP2008513113A JP5245823B2 JP 5245823 B2 JP5245823 B2 JP 5245823B2 JP 2008513113 A JP2008513113 A JP 2008513113A JP 2008513113 A JP2008513113 A JP 2008513113A JP 5245823 B2 JP5245823 B2 JP 5245823B2
- Authority
- JP
- Japan
- Prior art keywords
- dysphagia
- capsinoid
- improving agent
- food composition
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019505 Deglutition disease Diseases 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 title description 17
- 235000013305 food Nutrition 0.000 title description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 3
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- BXBVPYSHEOQGHP-UHFFFAOYSA-N Nordihydrocapsiate Chemical compound COC1=CC(COC(=O)CCCCCC(C)C)=CC=C1O BXBVPYSHEOQGHP-UHFFFAOYSA-N 0.000 description 14
- 235000002566 Capsicum Nutrition 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 241000208293 Capsicum Species 0.000 description 12
- RBCYRZPENADQGZ-UHFFFAOYSA-N Dihydrocapsiate Chemical compound COC1=CC(COC(=O)CCCCCCC(C)C)=CC=C1O RBCYRZPENADQGZ-UHFFFAOYSA-N 0.000 description 11
- 239000001390 capsicum minimum Substances 0.000 description 11
- 229960002504 capsaicin Drugs 0.000 description 10
- 235000017663 capsaicin Nutrition 0.000 description 10
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 10
- 230000011514 reflex Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 230000009747 swallowing Effects 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 235000019633 pungent taste Nutrition 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- ZICNYIDDNJYKCP-SOFGYWHQSA-N capsiate Chemical compound COC1=CC(COC(=O)CCCC\C=C\C(C)C)=CC=C1O ZICNYIDDNJYKCP-SOFGYWHQSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- -1 fatty acid ester Chemical class 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000199 molecular distillation Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VSINWHDOHWBJCS-UHFFFAOYSA-N (4-hydroxy-3-methoxyphenyl)methyl nonanoate Chemical compound CCCCCCCCC(=O)OCC1=CC=C(O)C(OC)=C1 VSINWHDOHWBJCS-UHFFFAOYSA-N 0.000 description 1
- WOQZUSJDLLGEHO-UHFFFAOYSA-N (4-hydroxy-3-methoxyphenyl)methyl octanoate Chemical compound CCCCCCCC(=O)OCC1=CC=C(O)C(OC)=C1 WOQZUSJDLLGEHO-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- XJQPQKLURWNAAH-UHFFFAOYSA-N dihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCC(C)C)=CC=C1O XJQPQKLURWNAAH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 210000003823 hyoid bone Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
すなわち本発明は、以下のとおりである。
(1)カプシノイドを含有することを特徴とする嚥下障害改善剤。
(2)前記嚥下障害改善剤を含有する医薬組成物。
(3)前記嚥下障害改善剤を含有する食品組成物。
(4)カプシノイドの含有量が1nmol/kg〜10 mmol/kgである前記食品組成物。
(5)食品組成物がトローチである前記食品組成物。
(6)嚥下障害を有する対象に、カプシノイドを含有する組成物を投与することにより、嚥下障害を改善する方法。
(7)嚥下障害改善用の医薬組成物の製造における、カプシノイドの使用。
本発明においてカプシノイドとは、バニリルアルコールの脂肪酸エステルをいい、その代表的成分としては、トウガラシ類に含有される成分として確認された、カプシエイト、ジヒドロカプシエイト、ノルジヒドロカプシエイトが含まれ、更に、バニリルデカノエイト、バニリルノナノエイト、バニリルオクタノエイト等の、カプシエイトやノルジヒドロカプシエイトと同程度の脂肪酸鎖長を有する、各種直鎖あるいは分岐鎖脂肪酸とバニリルアルコールの脂肪酸エステルをも包含するが、これらには制限されない。カプシエイト(4-hydoxy-3-methoxybenzyl (E)-8-methyl-6-nonenoate。以下、「CST」と略する場合がある)、ジヒドロカプシエイト(4-hydroxy-3-methoxybenzyl 8-methylnonanoate。以下、「DCT」と略する場合がある)、ノルジヒドロカプシエイト(4-hydroxy-3-methoxybenzyl 7-methyl-octanoate。以下、「NDCT」と略する場合がある)は、それぞれ以下の化学式を有する。
また、カプシノイドは、他のトウガラシ属に属する植物中にも存在することが確認されている(園芸学会雑誌58、601-607)。
[製造例]
「CH-19甘」の果実を粉砕し、凍結乾燥の後、3倍容のヘキサンを用いてソックスレー抽出器で油分を抽出した。その後溶媒を蒸発乾固し抽出組成物を得た。この抽出組成物に対して25重量%のトリカプリリン(理研ビタミン(株)製 M-2)を添加、大科工業(株)製流下式薄膜分子蒸留装置(蒸発加熱面積0.024m2、コンデンサ面積0.0088m2)を用い、蒸発加熱温度180℃、真空度12〜14Pa、油脂フィード量1.1g/min.の条件で分子蒸留を行い、カプシノイド含量約9.5%の抽出油を得た。この抽出油に含まれるカプシノイドの成分及び比率は、ノルジヒドロカプシエイト:カプシエイト:ジヒドロカプシエイト=17:60:23であった。また、尚、この抽出油には、約0.005%のカプサイシノイドが含有されると推定された。
以下の実施例においては、上記のようにして得られた抽出油70μLに、使用直前に乳化剤(Tween 80)1mL、99.7%エタノール 1mLを添加し、更に、実施例1においては生理食塩水(大塚)、実施例2においては蒸留水で希釈し、各種濃度のカプシノイド溶液を調製した。同様に、カプサイシン(シグマアルドリッチ社製)30.5mgに、使用直前に乳化剤(Tween 80)1mL、99.7%エタノール1mLを添加し、更に、実施例1においては生理食塩水(大塚)、実施例2においては蒸留水で希釈し、各種濃度のカプサイシン溶液を調製した。
健常成人17人(平均年齢 36±2.6才)に、製造例のカプサイシン溶液(0.49〜1000μM)をネブライザーを用いて一分間毎に15秒吸引させ、1回の吸引で5回以上咳が惹起された濃度(C5)を求めた。
この結果、カプサイシン及びカプシノイドによるC5は、それぞれ2.02μM、86.4μMであり、濃度差は43倍であった。一方、スコビル法による辛味刺激は、カプシノイドはカプサイシンの1000分の1であるため、カプシノイドによると辛味を惹起せずに咳反射を誘発できることが示された。
基礎疾患を有する高齢者男女3名に対し、鼻からカテーテルを口蓋垂の高さまで挿入し、コントロール(水)と各種濃度のカプシノイド溶液(0.1, 0.01, 0.001μM)を1ml滴下し、嚥下反射が起こるまでの潜時(秒、舌骨が挙上して下りてくるまでの時間)を測定した。結果を表1に示す。また、コントロールを100%としたときの潜時の3名の平均値を図1に示す。カプシノイド投与群では、顕著にコントロール時に比して嚥下反射が改善され、図1に示されるように容量依存的な嚥下反射時間の短縮が認められた。
Claims (4)
- カプシノイドを含有することを特徴とする嚥下障害改善剤。
- 請求項1に記載の嚥下障害改善剤を含有する嚥下障害改善用の医薬組成物。
- カプシノイドの含有量が1nmol/kg〜10nmol/kgである請求項2に記載の医薬組成物。
- 嚥下障害改善用の医薬組成物の製造における、カプシノイドの使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008513113A JP5245823B2 (ja) | 2006-04-24 | 2007-03-29 | 嚥下障害改善剤およびそれを含有する医薬又は食品組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006119319 | 2006-04-24 | ||
JP2006119319 | 2006-04-24 | ||
JP2008513113A JP5245823B2 (ja) | 2006-04-24 | 2007-03-29 | 嚥下障害改善剤およびそれを含有する医薬又は食品組成物 |
PCT/JP2007/056823 WO2007125717A1 (ja) | 2006-04-24 | 2007-03-29 | 嚥下障害改善剤およびそれを含有する医薬又は食品組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007125717A1 JPWO2007125717A1 (ja) | 2009-09-10 |
JP5245823B2 true JP5245823B2 (ja) | 2013-07-24 |
Family
ID=38655252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008513113A Active JP5245823B2 (ja) | 2006-04-24 | 2007-03-29 | 嚥下障害改善剤およびそれを含有する医薬又は食品組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9420817B2 (ja) |
EP (1) | EP2011494B1 (ja) |
JP (1) | JP5245823B2 (ja) |
ES (1) | ES2429288T3 (ja) |
PT (1) | PT2011494E (ja) |
WO (1) | WO2007125717A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101848709A (zh) * | 2007-11-19 | 2010-09-29 | 雀巢产品技术援助有限公司 | 口咽吞咽困难的治疗 |
JP6324951B2 (ja) * | 2013-05-10 | 2018-05-16 | 国立大学法人徳島大学 | 嚥下障害の治療薬 |
JP6879297B2 (ja) * | 2016-04-13 | 2021-06-02 | 味の素株式会社 | 加齢に伴う身体機能低下もしくは身体機能障害、または加齢に伴う精神機能低下もしくは精神機能障害の抑制または改善用組成物 |
JP7020265B2 (ja) * | 2018-04-18 | 2022-02-16 | 味の素株式会社 | カプシノイドの抽出方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11246478A (ja) * | 1998-03-04 | 1999-09-14 | Morinaga & Co Ltd | エステル結合を有する新規なカプサイシノイド様物質 |
WO2004058301A1 (ja) * | 2002-12-26 | 2004-07-15 | Yamada Apiculture Center, Inc. | 嚥下反射障害改善用組成物 |
JP2005000161A (ja) * | 2003-01-28 | 2005-01-06 | Morinaga & Co Ltd | トウガラシ又はカプシノイド含有植物の発酵組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5762963A (en) * | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
US6159473A (en) * | 1998-06-24 | 2000-12-12 | Botanical Laboratories, Inc. | Sore throat spray |
JP3092006B1 (ja) | 1999-04-30 | 2000-09-25 | 森永製菓株式会社 | 新規なカプサイシノイド様物質の合成法 |
JP2001026538A (ja) | 1999-07-13 | 2001-01-30 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する食品及び医薬組成物 |
US20030082249A1 (en) * | 2001-10-26 | 2003-05-01 | Ovation Pharmaceuticals | Compositions containing capsaicin and its derivatives, and their use in treating mucositis |
JP4089306B2 (ja) | 2002-06-14 | 2008-05-28 | 味の素株式会社 | カプシノイド抽出物の製造方法、及び該方法によって得られるカプシノイド抽出物 |
JP2004107285A (ja) | 2002-09-20 | 2004-04-08 | Mercian Corp | 嚥下障害改善剤 |
PT1627634E (pt) * | 2003-05-15 | 2013-10-24 | Ajinomoto Kk | Composição para redução de lípidos no organismo |
US9399030B2 (en) * | 2005-02-01 | 2016-07-26 | Ajinomoto Co., Inc. | Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same |
JP5109972B2 (ja) * | 2006-03-31 | 2012-12-26 | 味の素株式会社 | カプシノイド含有飲食品の製造方法 |
-
2007
- 2007-03-29 PT PT77402618T patent/PT2011494E/pt unknown
- 2007-03-29 ES ES07740261T patent/ES2429288T3/es active Active
- 2007-03-29 WO PCT/JP2007/056823 patent/WO2007125717A1/ja active Application Filing
- 2007-03-29 EP EP07740261.8A patent/EP2011494B1/en active Active
- 2007-03-29 JP JP2008513113A patent/JP5245823B2/ja active Active
-
2008
- 2008-10-24 US US12/257,830 patent/US9420817B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11246478A (ja) * | 1998-03-04 | 1999-09-14 | Morinaga & Co Ltd | エステル結合を有する新規なカプサイシノイド様物質 |
WO2004058301A1 (ja) * | 2002-12-26 | 2004-07-15 | Yamada Apiculture Center, Inc. | 嚥下反射障害改善用組成物 |
JP2005000161A (ja) * | 2003-01-28 | 2005-01-06 | Morinaga & Co Ltd | トウガラシ又はカプシノイド含有植物の発酵組成物 |
Non-Patent Citations (1)
Title |
---|
JPN6012039160; 佐々木英忠ら: '不顕性誤嚥の予防(とうがらしの効能)' 化学療法の領域 Vol.14, No.2, 1998, 91-97 * |
Also Published As
Publication number | Publication date |
---|---|
US9420817B2 (en) | 2016-08-23 |
US20090281182A1 (en) | 2009-11-12 |
EP2011494A1 (en) | 2009-01-07 |
JPWO2007125717A1 (ja) | 2009-09-10 |
ES2429288T3 (es) | 2013-11-14 |
PT2011494E (pt) | 2013-08-29 |
EP2011494B1 (en) | 2013-08-21 |
EP2011494A4 (en) | 2009-04-29 |
WO2007125717A1 (ja) | 2007-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018058903A (ja) | 成長ホルモン分泌促進剤 | |
JP5245823B2 (ja) | 嚥下障害改善剤およびそれを含有する医薬又は食品組成物 | |
JPH08225453A (ja) | リポプロテイン(a)低下剤及びコレステロール低下剤並びにこれを含有する医薬 | |
JP2008237117A (ja) | 抗疲労食品素材及び抗疲労食品 | |
KR20070027645A (ko) | 지방 연소 촉진제 | |
KR20190043997A (ko) | 국화 및 황금 혼합 추출물을 유효성분으로 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물 | |
JP4002654B2 (ja) | 血中脂質改善剤、サイクリックampホスホジエステラーゼ阻害剤、及び肥満の予防・解消剤、並びに飲食品及び皮膚外用剤 | |
JP2014024774A (ja) | 睡眠の質改善剤 | |
KR100828069B1 (ko) | 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,지방간의 예방 또는 치료용 조성물 | |
KR102189109B1 (ko) | 한약재 지용성 분획 추출물을 유효성분으로 함유하는 천식의 개선, 예방 또는 치료용 조성물 | |
JP6709001B1 (ja) | TNF−α又はIL−6産生抑制用組成物 | |
JP4560864B2 (ja) | 新規なカプサイシノイド様物質を含有する鎮痛剤、食品及び飼料 | |
JP4907280B2 (ja) | リパーゼ阻害剤 | |
JP2004107285A (ja) | 嚥下障害改善剤 | |
KR101332824B1 (ko) | 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물 | |
KR20150105552A (ko) | 마황, 대황 및 자초의 혼합 추출물을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
JP5969308B2 (ja) | 血管内皮細胞の一酸化窒素分泌促進剤又は分泌誘導剤 | |
JP7452777B2 (ja) | 生活の質改善又は維持用組成物 | |
JP2012131823A (ja) | 線毛運動活性化剤及びそれを含む飲食品 | |
KR102542119B1 (ko) | 애기우산나물 추출물을 유효성분으로 포함하는 미세먼지 유발 염증성 기도 질환의 예방 또는 치료용 조성물 | |
EP4151226A1 (en) | Coronavirus therapeutic agent comprising zanthoxylum piperitum leaf extract as active ingredient | |
JP2004051608A (ja) | 大腸潰瘍の改善予防剤 | |
JP2003342172A (ja) | カプサイシノイド様物質を含有する糖尿病血糖値低下組成物およびカプサイシノイド様物質の糖尿病血糖値低下剤としての使用 | |
WO2021247447A1 (en) | Antiviral compositions | |
JP2012131822A (ja) | 線毛運動活性化剤及びそれを含む飲食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120914 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130122 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130312 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130325 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5245823 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160419 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |